Distribution of systemically administered nanoparticles reveals a size-dependent effect immediately following cardiac ischaemia-reperfusion injury

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lundy, David J ^a   Chen, Kun Hung ^a   Toh, Elsie K W ^a   Hsieh, Patrick C H ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL DERIVATIVE; NANOPARTICLE; POLYSTYRENE DERIVATIVE;

ANIMAL; CARDIAC MUSCLE; CHEMISTRY; DRUG DELIVERY SYSTEM; HEART VENTRICLE; MALE; METABOLISM; MOUSE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PARTICLE SIZE; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TIME FACTOR; TISSUE DISTRIBUTION;

ANIMALS; DRUG DELIVERY SYSTEMS; HEART VENTRICLES; MALE; MICE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYSTYRENES; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84966705302     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25613     Document Type: Article

References (47)

1. Lloyd-Jones D, et al. Executive summary: Heart disease, and stroke statistics-2010 update: A report from the american heart association. Circulation. 121, 46-215 (2010
2. Yang X, Pabon L, & Murry C. E. Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 114, 511-523 (2014
3. Laflamme M. a, & Murry C. E. Regenerating the heart. Nat. Biotechnol. 23, 845-856 (2005
4. Vilahur G, et al. Molecular, and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol. 50, 522-533 (2011
5. Ojha N, et al. Characterization of the structural, and functional changes in the myocardium following focal ischaemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 294, H2435-H2443 (2008
6. OGara P, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 128, e240-e327 (2013
7. Dirksen M. T, Laarman G. J, Simoons M. L, & Duncker D. J. G. M. Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc. Res. 74, 343-355 (2007
8. Dargie H. Heart failure post-myocardial infarction: a review of the issues. Heart 91 Suppl 2, ii3-i6; discussion ii31, ii43-i48 (2005
9. Gerczuk P. Z, & Kloner R. a. An update on cardioprotection: A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J. Am. Coll. Cardiol. 59, 969-978 (2012
10. Prasad A, Stone G. W, Holmes D. R, & Gersh B. Reperfusion injury, microvascular dysfunction, and cardioprotection: The dark side of reperfusion. Circulation. 120, 2105-2112 (2009
11. Hausenloy D, & Yellon D. Myocardial ischaemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 123, 92-100 (2013
12. Staat P. Postconditioning the Human Heart. Circulation. 112, 2143-2148 (2005
13. Nguyen M. M, Gianneschi N. C, & Christman K. L. Developing injectable nanomaterials to repair the heart. Curr. Opin. Biotechnol. 34, 225-231 (2015
14. Projahn D, et al. Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction. J. Cell. Mol. Med. n/a-n/a. doi: 10.1111/jcmm.12225 (2014
15. Eckhouse S. R. Local Hydrogel Release of Recombinant TIMP-3 Attenuates Adverse Left Ventricular Remodeling After Experimental Myocardial Infarction. Sci Transl Med 6, 223ra21 (2014
16. Kloner R. a. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ. Res. 113, 451-463 (2013
17. Salimath A. S, et al. Dual Delivery of Hepatocyte, and Vascular Endothelial Growth Factors via a Protease-Degradable Hydrogel Improves Cardiac Function in Rats. PLoS One 7, e50980 (2012
18. Seif-Naraghi S. B, et al. Safety, and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci. Transl. Med. 5, 173ra25 (2013
19. Engel F. B, Hsieh P. C, Lee R. T, & Keating M. T. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci USA. 103, 15546-15551 (2006
20. Chang M. Y, et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J. Control. Release. 170, 287-294 (2013
21. Laham R. J, et al. Intracoronary, and intravenous administration of basic fibroblast growth factor: myocardial, and tissue distribution. Drug Metab Dispos. 27, 821-826 (1999
22. Fang J, Nakamura H, & Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations, and augmentation of the effect. Advanced Drug Delivery Reviews. 63, 136-151 (2011
23. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background, and future prospects. Bioconjugate Chemistry. 21, 797-802 (2010
24. Weis S. M. Vascular permeability in cardiovascular disease, and cancer. Curr. Opin. Hematol. 15, 243-249 (2008
25. Goldfarb J. W, Arnold S, & Han J. Recent myocardial infarction: assessment with unenhanced T1-weighted MR imaging. Radiology. 245, 245-250 (2007
26. Prabhakar U, et al. Challenges, and key considerations of the enhanced permeability, and retention effect for nanomedicine drug delivery in oncology. In Cancer Research. 73, 2412-2417 (2013
27. Schipper M. L, et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 5, 126-134 (2009
28. He C, Hu Y, Yin L, Tang C, & Yin C. Effects of particle size, and surface charge on cellular uptake, and biodistribution of polymeric nanoparticles. Biomaterials. 31, 3657-3666 (2010
29. Hirn S, et al. Particle size-dependent, and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur. J. Pharm. Biopharm. 77, 407-416 (2011
30. Huang X, et al. The Shape Effect of Mesoporous Silica Nanoparticles on Biodistribution, Clearance, and Biocompatibility in vivo. ACS Nano 5, 5390-5399 (2011
31. Dos Santos T, Varela J, Lynch I, Salvati A, & Dawson K. A. Quantitative assessment of the comparative nanoparticle-uptake efficiency of a range of cell lines. Small 7, 3341-3349 (2011
32. Liao W.-Y, et al. Comprehensive characterizations of nanoparticle biodistribution following systemic injection in mice. Nanoscale 5, 11079-11086 (2013
33. Yaehne K, et al. Nanoparticle accumulation in angiogenic tissues: Towards predictable pharmacokinetics. Small 9, 3118-3127 (2013
34. Chen K.-H, et al. Nanoparticle distribution during systemic inflammation is size-dependent, and organ-specific. Nanoscale 7, 15863-15872 (2015
35. May R. C, & Machesky L. M. Phagocytosis, and the actin cytoskeleton. J. Cell Sci. 114, 1061-1077 (2001
36. Paulis L. E, et al. Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J. Control. Release. 162, 276-285 (2012
37. Dvir T, et al. Nanoparticles targeting the infarcted heart. Nano Lett. 11, 4411-4414 (2011
38. Nguyen J, et al. Delivery of lipid micelles into infarcted myocardium using a lipid-linked matrix metalloproteinase targeting Peptide. Mol Pharm. 12, 1150-1157 (2015
39. Khan R. S, et al. Targeting extracellular DNA to deliver IGF-1 to the injured heart. Sci. Rep. 4, 4257 (2014
40. Fredman G, et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7 (2015
41. Lee D, et al. H2O2-responsive molecularly engineered polymer nanoparticles as ischaemia/reperfusion-Targeted nanotherapeutic agents. Sci. Rep. 3, 2233 (2013
42. Wohlfart S, Gelperina S, & Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 161, 264-273 (2012
43. Liu S. Q, Tefft B. J, Zhang B, Liu C, & Wu Y. H. Regulation of Hepatic Cell Mobilization in Experimental Myocardial Ischaemia. Cell. Mol. Bioeng. 4, 693-707 (2011
44. Liu S. Q, et al. Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischaemia. Am. J. Physiol. Heart Circ. Physiol. 303, H1446-58 (2012
45. Chan J. M, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl. Acad. Sci. USA. 107, 2213-2218 (2010
46. Won Y. W, McGinn A. N, Lee M, Bull D. A, & Kim S. W. Targeted gene delivery to ischemic myocardium by homing peptideguided polymeric carrier. Mol. Pharm. 10, 378-385 (2013
47. Kutscher H. L, et al. Enhanced passive pulmonary targeting, and retention of PEGylated rigid microparticles in rats. Int. J. Pharm. 402, 64-71 (2010